MedPath

Photobiomodulation in Pulmonary Fibrosis post Covid-19

Not Applicable
Recruiting
Conditions
pulmonary fibrosis
C01.748.610.763.500
Registration Number
RBR-7csg79n
Lead Sponsor
Centro Universitário de Itajubá
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
Not specified
Inclusion Criteria

Patients with post-COVID-19 pulmonary fibrosis; aged between 51 and 81 years; both genders

Exclusion Criteria

Patients with thromboembolic alterations such as Deep Vein Thrombosis (DVT) and Pulmonary Embolism; tracheostomized; with a body mass index (BMI) >29.9 kgm2; who had neoplasms; history of photosensitivity; who had previously undergone Cardiopulmonary rehabilitation

Study & Design

Study Type
Intervention
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
It is expected that the photobiomodulation technique with low-intensity light, using near-infrared LEDs, in association with cardiopulmonary rehabilitation through aerobic exercises, will be effective in the treatment of patients with post-COVID-19 pulmonary fibrosis
Secondary Outcome Measures
NameTimeMethod
A positive effect of LED therapy on the lung function of post-COVID-19 patients is expected, in addition to the resulting improvement in respiratory muscle performance, through the analysis of Maximum Inspiratory Pressure (MIP) and Maximum Expiratory Pressure (MEP) and better performance cardiopulmonary by means of the distance covered in the 6MWT. We will find improvement in cardiopulmonary capacity through the Functional Status Scale (PCFS) and better clinical recovery of the patient through verification of pulse oximetry and complaint of dyspnea on exertion
© Copyright 2025. All Rights Reserved by MedPath